• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

NIDA IRP

National Institute on Drug Abuse - Intramural Research Program

  National Institute on Drug Abuse | NIH IRP | Treatment Info | Emergency Contacts
  • Home
  • News
    • Featured Paper of the Month
    • Reviews to Read
    • Hot off the Press
    • IRP News
    • Awards
    • Technology Development Initiative Paper of the Month
    • Seminar Series
    • Addiction Grand Rounds
  • About
    • About NIDA IRP
    • Contact Us
    • Directions and Map
    • Careers at NIDA IRP
    • Emergency Contacts
    • Employee Assistance Resources
  • Organization
    • Faculty
    • Office of the Scientific Director
    • Office of the Clinical Director
    • Office of Education and Career Development
    • Administrative Management Branch
    • Molecular Targets and Medications Discovery Branch
    • Cellular and Neurocomputational Systems Branch
    • Molecular Neuropsychiatry Research Branch
    • Neuroimaging Research Branch
    • Behavioral Neuroscience Research Branch
    • Integrative Neuroscience Research Branch
    • Translational Addiction Medicine Branch
    • Core Facilities
    • Community Outreach Group
  • Training Programs
    • Office of Education and Career Development
    • OECD Awards
    • Summer Internship Program
    • Postbaccalaureate Program
    • Graduate Partnership Program
    • Postdoctoral Program
    • NIDA Speakers Bureau
    • Clinical Electives Program
    • Clinical Mentoring Program
  • Study Volunteers

Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.

Hot Off the Press! – August 2017

Gomez, Juan L; Bonaventura, Jordi; Lesniak, Wojciech; Mathews, William B; Sysa-Shah, Polina; Rodriguez, Lionel A; Ellis, Randall J; Richie, Christopher T; Harvey, Brandon K; Dannals, Robert F; Pomper, Martin G; Bonci, Antonello; Michaelides, Michael

Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Journal Article

In: Science, vol. 357, no. 6350, pp. 503–507, 2017, ISSN: 1095-9203 (Electronic); 0036-8075 (Linking).

Abstract | Links

@article{Gomez2017,
title = {Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.},
author = {Juan L Gomez and Jordi Bonaventura and Wojciech Lesniak and William B Mathews and Polina Sysa-Shah and Lionel A Rodriguez and Randall J Ellis and Christopher T Richie and Brandon K Harvey and Robert F Dannals and Martin G Pomper and Antonello Bonci and Michael Michaelides},
url = {https://www.ncbi.nlm.nih.gov/pubmed/28774929},
doi = {10.1126/science.aan2475},
issn = {1095-9203 (Electronic); 0036-8075 (Linking)},
year = {2017},
date = {2017-08-04},
urldate = {2017-08-04},
journal = {Science},
volume = {357},
number = {6350},
pages = {503--507},
address = {Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse (NIDA) Intramural Research Program, Baltimore, MD 21224, USA.},
abstract = {The chemogenetic technology DREADD (designer receptors exclusively activated by designer drugs) is widely used for remote manipulation of neuronal activity in freely moving animals. DREADD technology posits the use of "designer receptors," which are exclusively activated by the "designer drug" clozapine N-oxide (CNO). Nevertheless, the in vivo mechanism of action of CNO at DREADDs has never been confirmed. CNO does not enter the brain after systemic drug injections and shows low affinity for DREADDs. Clozapine, to which CNO rapidly converts in vivo, shows high DREADD affinity and potency. Upon systemic CNO injections, converted clozapine readily enters the brain and occupies central nervous system-expressed DREADDs, whereas systemic subthreshold clozapine injections induce preferential DREADD-mediated behaviors.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

The chemogenetic technology DREADD (designer receptors exclusively activated by designer drugs) is widely used for remote manipulation of neuronal activity in freely moving animals. DREADD technology posits the use of "designer receptors," which are exclusively activated by the "designer drug" clozapine N-oxide (CNO). Nevertheless, the in vivo mechanism of action of CNO at DREADDs has never been confirmed. CNO does not enter the brain after systemic drug injections and shows low affinity for DREADDs. Clozapine, to which CNO rapidly converts in vivo, shows high DREADD affinity and potency. Upon systemic CNO injections, converted clozapine readily enters the brain and occupies central nervous system-expressed DREADDs, whereas systemic subthreshold clozapine injections induce preferential DREADD-mediated behaviors.

Close

  • https://www.ncbi.nlm.nih.gov/pubmed/28774929
  • doi:10.1126/science.aan2475

Close

Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.

Primary Sidebar

News

  • All News and Featured Publications
  • Featured Paper of the Month
  • Hot off the Press
  • Reviews to Read
  • IRP News
  • Awards
  • Technology Development Initiative Paper of the Month
  • Seminar Series
Home / News Main / Hot off the Press / Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
  • National Institute on Drug Abuse
  • NIH Intramural Research Program
  • National Institutes of Health
  • Health and Human Services
  • USA.GOV
  • Emergency Contacts
  • Employee Assistance
  • Treatment Information
  • Contact Us
  • Careers at NIDA IRP
  • Accessibility
  • Privacy
  • HHS Vulnerability Disclosure
  • Freedom of Information Act
  • Document Viewing Tools
  • Offsite Links
  • National Institute on Drug Abuse
  • NIH Intramural Research Program
  • National Institutes of Health
  • Health and Human Services
  • USA.GOV
  • Emergency Contacts
  • Employee Assistance
  • Treatment Information
  • Contact Us
  • Careers at NIDA IRP
  • Accessibility
  • Privacy
  • HHS Vulnerability Disclosure
  • Freedom of Information Act
  • Document Viewing Tools
  • Offsite Links

  • Home
  • News
    ▼
    • Featured Paper of the Month
    • Reviews to Read
    • Hot off the Press
    • IRP News
    • Awards
    • Technology Development Initiative Paper of the Month
    • Seminar Series
    • Addiction Grand Rounds
  • About
    ▼
    • About NIDA IRP
    • Contact Us
    • Directions and Map
    • Careers at NIDA IRP
    • Emergency Contacts
    • Employee Assistance Resources
  • Organization
    ▼
    • Faculty
    • Office of the Scientific Director
    • Office of the Clinical Director
    • Office of Education and Career Development
    • Administrative Management Branch
    • Molecular Targets and Medications Discovery Branch
    • Cellular and Neurocomputational Systems Branch
    • Molecular Neuropsychiatry Research Branch
    • Neuroimaging Research Branch
    • Behavioral Neuroscience Research Branch
    • Integrative Neuroscience Research Branch
    • Translational Addiction Medicine Branch
    • Core Facilities
    • Community Outreach Group
  • Training Programs
    ▼
    • Office of Education and Career Development
    • OECD Awards
    • Summer Internship Program
    • Postbaccalaureate Program
    • Graduate Partnership Program
    • Postdoctoral Program
    • NIDA Speakers Bureau
    • Clinical Electives Program
    • Clinical Mentoring Program
  • Study Volunteers